Hims Hers Health Inc (HIMS)vsZoetis Inc (ZTS)
HIMS
Hims Hers Health Inc
$28.09
-14.20%
HEALTHCARE · Cap: $6.50B
ZTS
Zoetis Inc
$75.35
+1.05%
HEALTHCARE · Cap: $32.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 302% more annual revenue ($9.53B vs $2.37B). ZTS leads profitability with a 28.0% profit margin vs -0.0%. ZTS appears more attractively valued with a PEG of 1.84. ZTS earns a higher WallStSmart Score of 66/100 (B-).
HIMS
Avoid29
out of 100
Grade: F
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.1%
Fair Value
$25.32
Current Price
$28.09
$2.77 premium
Margin of Safety
+11.0%
Fair Value
$144.62
Current Price
$75.35
$69.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
Trading at 14.6x book value
0.0% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 9.6x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
HIMS has a balanced fundamental profile.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : HIMS
The primary concerns for HIMS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.54 is elevated, increasing financial risk.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
HIMS profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.34 — expect wider price swings.
ZTS is growing revenue faster at 2.9% — sustainability is the question.
ZTS generates stronger free cash flow (291M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (66/100 vs 29/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?